Tango is an oncology biotechnology company with focus is on exploiting synthetic lethal interactions to discover and develop new breakthrough cancer therapies.
Our discovery efforts begin and end with patients. We have inverted the traditional discovery paradigm with our target discovery platform, where the discovery of novel targets and the associated patient selection strategy are integrated into a single experimental design. Our platform uses cutting-edge CRISPR technologies to identify novel targets for genetically-defined groups of cancer patients. We leverage the principles of synthetic lethality to find novel dependencies in cancer cells and identify the relevant drug targets. As we advance our molecules into the clinic, our trials will enroll the patients most likely to benefit from our new treatments as identified in the target discovery profess, thereby enabling greater speed, success, and impact for those patients.